JMJacques Mallet

Jacques Mallet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jacques Mallet has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Inactivation of the orphan G protein-coupled receptor Gpr88 in the dorsal striatum reverses the effects of dopamine depletion in a rat model of Parkinson’s disease

    by R. Meloni, J. Pegon, N. Faucon Biguet, B. Galet, A. Do Thi, J. Mallet, M.J. Millan, C. Mannoury la Cour, M. Ingallinesi

  • Open Access

    Zinc Finger Protein 191 (ZNF191/Zfp191) Is Necessary to Maintain Neural Cells As Cycling Progenitors

    by Olfa Khalfallah, Philippe Ravassard, Che Serguera Lagache, Cécile Fligny, Angéline Serre, Elisa Bayard, Nicole Faucon-Biguet, Jacques Mallet, Rolando Meloni, Jeannette Nardelli

    The identification of the factors that allow better monitoring of stem cell renewal and differentiation is of paramount importance for the implementation of new regenerative therapies, especially with regard to the nervous and hematopoietic systems. In this article, we present new information on the function of zinc finger protein 191 (ZNF/Zfp191), a factor isolated in hematopoietic cell lines, within progenitors of the central nervous system (CNS). ZNF/Zfp191 has been found to be principally expressed in progenitors of the developing CNS of humans and mice. Such an overlap of the expression patterns in addition to the high homology of the protein in mammals suggested that ZNF/Zfp191 exerts a conserved function within such progenitors. Indeed, ZNF191 knockdown in human neural progenitors inhibits proliferation and leads to the exit of the cell cycle. Conversely, ZNF191 misexpression maintains progenitors in cycle and exerts negative control on the Notch pathway, which prevents them from differentiating. The present data, together with the fact that the inactivation of Zfp191 leads to embryonic lethality, confirm ZNF191 as an essential factor acting for the promotion of the cell cycle and thus maintenance in the progenitor stage. On the bases of expression data, such a function can be extended to progenitor cells of other tissues such as the hematopoietic system, which emphasizes the important issue of further understanding the molecular events controlled by ZNF/Zfp191. Disclosure of potential conflicts of interest is found at the end of this article.


  • Maternal serotonin is crucial for murine embryonic development

    by Francine Côté, Cécile Fligny, Elisa Bayard, Jean-Marie Launay, Michael D. Gershon, Jacques Mallet, Guilan Vodjdani

    The early appearance of serotonin and its receptors during prenatal development, together with the many effects serotonin exerts during CNS morphogenesis, strongly suggest that serotonin influences the development and maturation of the mammalian brain before it becomes a neuromodulator/neurotransmitter. Sites of early serotonin biosynthesis, however, have not been detected in mouse embryos or extraembryonic structures, suggesting that the main source of serotonin could be of maternal origin. This hypothesis was tested by using knockout mice lacking the tph1 gene, which is responsible for the synthesis of peripheral serotonin. Genetic crosses were performed to compare the phenotype of pups born from homozygous and heterozygous mothers. Observations provide the first clear evidence that ( i ) maternal serotonin is involved in the control of morphogenesis during developmental stages that precede the appearance of serotonergic neurons and ( ii ) serotonin is critical for normal murine development. Most strikingly, the phenotype of tph1 −/− embryos depends more on the maternal genotype than on that of the concepti. Consideration of the maternal genotype may thus help to clarify the influence of other genes in complex diseases, such as mental illness.


  • Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo

    by Stéphanie Philippe, Chamsy Sarkis, Martine Barkats, Hamid Mammeri, Charline Ladroue, Caroline Petit, Jacques Mallet, Che Serguera

    Lentivirus-derived vectors are among the most promising viral vectors for gene therapy currently available, but their use in clinical practice is limited by the associated risk of insertional mutagenesis. We have overcome this problem by developing a nonintegrative lentiviral vector derived from HIV type 1 with a class 1 integrase (IN) mutation (replacement of the 262 RRK motif by AAH). We generated and characterized HIV type 1 vectors carrying this deficient enzyme and expressing the GFP or neomycin phosphotransferase transgene ( NEO ) under control of the immediate early promoter of human CMV. These mutant vectors efficiently transduced dividing cell lines and nondividing neural primary cultures in vitro . After transduction, transient GFP fluorescence was observed in dividing cells, whereas long-term GFP fluorescence was observed in nondividing cells, consistent with the viral genome remaining episomal. Moreover, G418 selection of cells transduced with vectors expressing the NEO gene showed that residual integration activity was lower than that of the intact IN by a factor of 500–1,250. These nonintegrative vectors were also efficient in vivo , allowing GFP expression in mouse brain cells after the stereotactic injection of IN-deficient vector particles. Thus, we have developed a generation of lentiviral vectors with a nonintegrative phenotype of great potential value for secure viral gene transfer in clinical applications.


  • Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease?

    by N A Do Thi, P Saillour, L Ferrero, T Paunio, J Mallet

    The transfer of the Glial cell line-derived neurotrophic factor (GDNF) gene to the central nervous system by a recombinant adenoviral vector (Ad) was studied. We constructed the adenovirus vector Ad-NSE-GDNF from which the E1, E3/E4 regions of Ad5 have been deleted and in which the GDNF gene was under the control of a neuron-specific enolase (NSE) promoter. The vector was injected into the striatum of a rat model of Parkinson's disease. We found that (i) the NSE promoter can restrict transgene expression in neurons; (ii) Ad-NSE-GDNF significantly protected dopaminergic (DA) neurons in the substantia nigra (SN) but did not reverse the impairments of amphetamine-induced rotational behavior in lesioned rats.


    • 29 December 1995
      • Vol. 7  (1) , 373-8

    Specific and efficient gene transfer strategy offers new potentialities for the treatment of motor neurone diseases.

    by F Finiels, M Gimenez Y Ribotta, M Barkats, M L Samolyk, J J Robert, A Privat, F Revah, J Mallet

    Several growth factors are candidates for the therapy of motor neurone diseases. However, there is no efficient, safe, and practicable administration route which hampers the clinical use of these potentially therapeutic agents. We show that specific and high yield gene transfer into motor neurones can be obtained by peripheral intramuscular injections of recombinant adenoviruses. These vectors are retrogradely transported from muscular motor units to motor neurone cell bodies. Gene transfer can thus be specifically targeted to particular regions of the spinal cord by appropriate choice of the injected muscle. The efficiency of gene transfer is high, with 58-100% of the motor neurones afferent to the injected muscle expressing the transgene. This new therapeutic protocol allows specific targeting of motor neurones without lesioning the spinal cord, and should avoid undesirable side effects associated with systemic administration of therapeutic factors.


    • 1 January 1995
      • Vol. 3  (5) , 317-21

    Adenovirus for neurodegenerative diseases: in vivo strategies and ex vivo gene therapy using human neural progenitors.

    by O Sabaté, M Barkats, M H Buc-Caron, M N Castel-Barthe, F Finiels, P Horellou, F Revah, J Mallet

    The discovery of major neurodegenerative mechanisms has opened the way to the development of novel therapeutic approaches. Gene therapy now enables researchers to overcome certain problems inherent to pharmacotherapy and to the grafting of embryonic cells. The production of recombinant adenoviruses are promising for in vivo gene therapy involving neuroprotective (Ad-SOD), neurotrophic (Ad-NGF) as well as restorative (Ad-TH) strategies. In addition, human neural progenitors offer great potential as vehicles for ex vivo gene therapy to replace degenerated cells in advanced stages of neurodegenerative diseases. This paper describes the clinical values of the new generations of adenoviral vectors.

  • AP‐1 complex and c‐fos transcription are involved in TPA provoked and trans‐synaptic inductions of the tyrosine hydroxylase gene: Insights into long‐term regulatory mechanisms

    by C. Icard‐Liepkalns, N. Faucon Biguet, S. Vyas, J. J. Robert, P. Sassone‐Corsi, J. Mallet

    We have previously shown that the phorbol ester, TPA, which activates protein kinase C, causes, in PC12 cells, a transcriptional activation of tyrosine hydroxylase (TH), the key enzyme in catecholamine synthesis. The study has now been extended to examine the processes that underlie this transcriptional stimulation and, in addition, to seek whether similar mechanisms are involved in long-term trans-synaptic induction of the TH gene in adrenal medullae of rats that have been given a single injection of reserpine. In both systems, it was found that the induction of c-fos gene transcription was associated with that of the TH gene but with different kinetics. The promoter of the TH gene contains (at position −207/–200) a sequence (TGATTCA) which differs from the consensus TRE or AP-1 site (TGACTCA) by one nucleotide. Experiments were carried out to investigate whether the AP-1 protein complex which is known to contain Fos and Jun binds to the putative TRE region of the TH promoter. In the gel shift assays, the nuclear protein extracts derived from TPA-treated PC12 cells and from AM of reserpine injected rats displayed a higher magnitude of binding to a 25-mer TRE-TH oligonucleotide as compared to controls. The results showed that the behaviour of TRE-TH was atypical in that two retarded complexes (A and B) were observed, which were displaced by specific competitors. Trans-activation experiments with plasmids TRE-TH/TK/CAT and −754/–19 TH/pUC18-CAT in PC12 cells showed an increase in CAT activity in response to TPA that correlates with the previously observed increase in TH transcriptional activity by TPA. Co-transfection with plasmids BK28 containing c-fos and/or with pSV-c-jun resulted in a significant increase in CAT activity showing a functional interaction of these proteins with TRE-TH. Our findings indicate that the TRE-TH site plays a critical role in trans-synaptic regulation of the TH gene.